Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. - Wikidata - wikimedia - TriplyDB

Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group.

Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group.

http://www.wikidata.org/entity/Q34059674

about

Risk factors for oligodendroglial tumors: a pooled international study Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas Clinical management of grade III oligodendroglioma International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy.Preirradiation gemcitabine chemotherapy for newly diagnosed glioblastoma. A phase II study.Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26)Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study.Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study.Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective Oligodendrogliomas in pediatric and adult patients: an outcome-based study from the Surveillance, Epidemiology, and End Result database Chemotherapy for high-grade gliomas.Central nervous system cancers Medical therapy of gliomas.Glioma classification: a molecular reappraisal.Effective long-term treatment with bevacizumab for relapsed glioblastoma: case report and review of the literature Quantitative proteomic analysis shows differentially expressed HSPB1 in glioblastoma as a discriminating short from long survival factor and NOVA1 as a differentiation factor between low-grade astrocytoma and oligodendroglioma.PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up.Therapy for recurrent malignant glioma in adults.Indications for Treatment: Is Observation or Chemotherapy Alone a Reasonable Approach in the Management of Low-Grade Gliomas?The Globalization of Cooperative Groups.Oligodendrogliomas: clinical significance of 1p and 19q chromosomal deletions.Chemotherapy for gliomas in mainland China: An overview.Molecular imaging of 1p/19q deletion in oligodendroglial tumours with 11C-methionine positron emission tomography Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131 Retrospective analysis of treatment outcome in 315 patients with oligodendroglial brain tumors.Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma.Correlation of histomorphologic prognostic markers and proliferative index with loss of heterozygosity 1p/19q and MGMT status in diffusely infiltrating gliomas.Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma Temozolomide salvage chemotherapy for recurrent anaplastic oligodendroglioma and oligo-astrocytoma.Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.Anaplastic oligodendroglioma.Patterns of care and survival for glioblastoma patients in the Veterans population.Chemotherapy in glioma.Anaplastic glioma: current treatment and management.Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor.

P2860

Q23910577-6D44F762-D51B-4E3F-865E-444AE9507603 Q24194645-2375D785-5DE3-463B-B501-6723B251FF22 Q24242968-CEA17C01-BE01-4A5F-B4AE-DD68F53249AA Q26801254-0F0A1F5A-C688-46B7-B5D5-B9D587EC225A Q30426724-01EAE0FB-5349-47E4-A47A-AED7F23EEE8B Q30542081-31A59C85-DD9A-4A70-93C5-0AB4E4641F27 Q30906322-B5EFE6DA-A04F-41F3-B94A-36BEFBF4510B Q31946792-988367E0-7D80-4E99-A889-47CB7F12F805 Q33260758-45A558BA-793E-4BB8-AB71-AB983C6A5818 Q33358921-D7390656-6E30-4627-BDDA-7F983F503B81 Q33387577-C136A035-8543-410A-B9EC-4B87733A83D4 Q33410196-6A22C427-B881-4DD8-8D13-D52DFB1A10B0 Q33636469-4DDB5D00-C0BB-49DA-9F2D-368A59233AB9 Q33649896-4ECBB8FC-127E-4BCA-BF1C-8675D2518F21 Q33898570-1A78FA77-0921-4477-8C58-AF93E8EC4138 Q34014740-BF36E6B6-70C5-4078-B160-F78C437AF4E3 Q34218761-97B316F2-2EBF-487F-B77A-6397894784B3 Q34363833-635A5090-71CC-4AD7-AAC1-A2C99300492F Q35580650-4BC21614-87ED-4376-A27E-AD764DF01524 Q35673519-0045EDDB-B7C9-4F48-9958-8D867D51A551 Q35746631-06A9F075-25ED-4AC2-A6ED-1C6E34537D9D Q35800584-DC80CFF4-DA16-4F39-8830-72649432C9C1 Q35918439-D6785A3D-62AB-4EC7-915B-182D3BBC978E Q36037100-1871B403-179B-48DA-A915-C7CBD2A8DEF8 Q36119749-FA08A532-B3B8-4240-91EE-157285A8F52D Q36307794-EB396C1D-851B-4702-8285-289457DEA538 Q36918752-DC8C714A-E0E3-4097-A840-DF23B02F4C0D Q37235829-127ED7BE-6BA6-4AB5-B1CD-038F96720EAA Q37284303-21219EC6-7643-4006-B905-C89CE47D972A Q37285711-B134A4BE-8BB1-44B7-AA3D-682C86DBC118 Q37355439-5F5D158E-6843-4BDA-A8DB-5066F3C67F9B Q37390680-1BD1DD6C-E1B3-4969-AA4E-5D95DC9B5EB3 Q37518265-895CCE44-B746-4E44-9301-984CCDB59949 Q37578075-D7D53BAA-3529-4E0D-BBA6-6D0B48A9625E Q37613957-CD7C063F-6B36-45FB-8777-553C3B7FD917 Q37714906-12664177-FECE-4555-BE9F-0AC606F129BA Q37924635-1C3026B9-557D-491D-8662-0FAA3D2806AC Q38438439-9FAA1F54-9DA8-4872-AF13-896406B6FDDC Q38456018-119F30D9-B973-4384-9251-363A7EB61336 Q38464426-2A65BED1-5CE2-4FA4-B7B4-4E1F3CCEAF7D

P2860

Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group.

http://www.wikidata.org/entity/Q34059674

description

1994 nî lūn-bûn

@nan

1994 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

1994 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

1994年の論文

@ja

1994年論文

@yue

1994年論文

@zh-hant

1994年論文

@zh-hk

1994年論文

@zh-mo

1994年論文

@zh-tw

1994年论文

@wuu

name

Chemotherapy for anaplastic ol ...... Canada Clinical Trials Group.

@ast

Chemotherapy for anaplastic ol ...... Canada Clinical Trials Group.

@en

Chemotherapy for anaplastic ol ...... Canada Clinical Trials Group.

@nl

type

label

Chemotherapy for anaplastic ol ...... Canada Clinical Trials Group.

@ast

Chemotherapy for anaplastic ol ...... Canada Clinical Trials Group.

@en

Chemotherapy for anaplastic ol ...... Canada Clinical Trials Group.

@nl

prefLabel

Chemotherapy for anaplastic ol ...... Canada Clinical Trials Group.

@ast

Chemotherapy for anaplastic ol ...... Canada Clinical Trials Group.

@en

Chemotherapy for anaplastic ol ...... Canada Clinical Trials Group.

@nl

P1433

Q34059674-031EC63A-A856-4CDF-B082-486FB4AACA97

P1476

Q34059674-DF16204D-1C76-49AE-AD07-0B17C5C2866A

P2093

Q34059674-01B518AF-AF3A-4AD9-ACBC-9DF8B16E233C

Q34059674-30DAC3AB-BDB2-417B-A3C8-2C17239EDEEA

Q34059674-5B99038F-5049-4CC6-A7CA-98340FD0961E

Q34059674-6A6E9017-8F58-457F-8D03-6EDCA918750B

Q34059674-97E182CD-AFCD-4928-9323-8B0DFD270937

Q34059674-9D4B109A-5906-480D-A7D9-BAB971558C8C

Q34059674-AF3C614E-CE45-4C03-A924-0A20E006C44E

Q34059674-D4D52ED2-E322-4875-9EE1-47AF23233E57

Q34059674-E41A23A5-32CF-457B-B9C0-9E484E681B98

Q34059674-FFB8CE2F-4AD7-4017-A3F1-376890F87DD2

P304

Q34059674-1FA8E363-2AA5-428B-9DAA-D3A54DB3DBBF

P31

Q34059674-2EE8D889-3BA6-47AE-8877-E23253BF5082

P356

Q34059674-762ADBB4-A284-4221-AA59-3121362E3B5C

P407

Q34059674-F55259F7-597E-4975-8FBD-2A49A6CA3D92

P433

Q34059674-091699E2-67F9-43BB-8E72-F81F464166FA

P478

Q34059674-CB6B91C3-310C-4175-AC68-01CB597E52AA

P577

Q34059674-23B7D084-CC39-4B61-BB3D-62C8FDE04D25

P698

Q34059674-C39617CB-63F7-4B11-B239-D5FA54C2FA94

P921

Q34059674-79385AF2-FA13-42D6-97F2-F40907E6F3FF

Q34059674-AEC6580E-9932-49BE-94E0-A5F41C68ECB1

Q34059674-CBDBEEC5-76AE-4615-961C-7BE9B2459C69

P356

JCO.1994.12.10.2013

P1433

Journal of Clinical Oncology

P1476

Chemotherapy for anaplastic ol ...... Canada Clinical Trials Group.

@en

P2093

C Schold

http://www.w3.org/2001/XMLSchema#string

D Fulton

http://www.w3.org/2001/XMLSchema#string

D Lee

http://www.w3.org/2001/XMLSchema#string

D Macdonald

http://www.w3.org/2001/XMLSchema#string

D Stewart

http://www.w3.org/2001/XMLSchema#string

E Dropcho

http://www.w3.org/2001/XMLSchema#string

G Cairncross

http://www.w3.org/2001/XMLSchema#string

J Buckner

http://www.w3.org/2001/XMLSchema#string

S Ludwin

http://www.w3.org/2001/XMLSchema#string

T Cascino

http://www.w3.org/2001/XMLSchema#string

P304

2013-2021

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.1994.12.10.2013

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

1994-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

7931469

http://www.w3.org/2001/XMLSchema#string

P921

oligodendroglioma